BRIEF published on 08/24/2026 at 08:10, 19 days 8 hours ago TME Pharma progresse vers des partenariats stratégiques pour la thérapie du cancer Glioblastome NOX-A12 Partenariats De Licence Tendances Du Marché Des Biotechnologies Transaction D'actions Du PDG
BRIEF published on 08/24/2026 at 08:10, 19 days 8 hours ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
PRESS RELEASE published on 08/24/2026 at 08:05, 19 days 8 hours ago TME Pharma fait le point sur ses activités TME Pharma fait le point sur ses activités et les négociations pour un accord de licence pour NOX-A12, médicament phare pour le cancer du cerveau. Analyse stratégique en cours Biotechnologie Accord De Licence TME Pharma NOX-A12 Cancer Du Cerveau
PRESS RELEASE published on 08/24/2026 at 08:05, 19 days 8 hours ago TME Pharma provides update on its activities TME Pharma provides update on its activities including final evaluation phase with potential partners for NOX-A12, with estimated peak sales potential of $1 billion, strategic decision framework, and scientific validation Clinical-stage Biotechnology License Agreement TME Pharma NOX-A12 Brain Cancer
BRIEF published on 10/30/2025 at 21:05, 10 months 12 days ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
BRIEF published on 10/30/2025 at 21:05, 10 months 12 days ago Rapport semestriel et restructuration financière de TME Pharma Résultats Financiers Biotechnologie Emission D'obligations Nomination Du PDG TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 10 months 12 days ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 1 year ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 1 year ago TME Pharma conclut avec succès sa levée de fonds d'août Biotechnologie Trésorerie Levée De Fonds Cryptomonnaies Cancer
BRIEF published on 09/01/2025 at 08:45, 1 year ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
Published on 09/12/2026 at 02:35, 13 hours 50 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 17 hours 25 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 18 hours 20 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 19 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 23 hours 25 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 8 hours 55 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 18 hours 10 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 18 hours 15 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 20 hours 40 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 22 hours 10 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 20 hours ago Availability of the 2026 Interim Financial Report
